Lucira Health (LHDX) to Release Quarterly Earnings on Thursday

Lucira Health (NASDAQ:LHDXGet Rating) will be announcing its earnings results after the market closes on Thursday, May 12th. Analysts expect the company to announce earnings of ($0.02) per share for the quarter. Lucira Health has set its Q1 2022 guidance at EPS and its FY 2022 guidance at EPS.Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Lucira Health (NASDAQ:LHDXGet Rating) last issued its quarterly earnings data on Thursday, March 10th. The company reported ($0.03) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.52. Lucira Health had a negative return on equity of 22.89% and a negative net margin of 69.67%. The business had revenue of $61.12 million during the quarter, compared to analysts’ expectations of $58.80 million. On average, analysts expect Lucira Health to post $1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of NASDAQ LHDX opened at $3.11 on Thursday. Lucira Health has a twelve month low of $2.54 and a twelve month high of $11.10. The stock has a fifty day simple moving average of $3.54 and a 200-day simple moving average of $5.21. The stock has a market capitalization of $123.93 million, a PE ratio of -1.63, a PEG ratio of 0.08 and a beta of 0.62.

In related news, insider Erik T. Engelson bought 30,000 shares of the stock in a transaction that occurred on Tuesday, March 15th. The stock was purchased at an average cost of $3.00 per share, with a total value of $90,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Millennium Management LLC lifted its holdings in Lucira Health by 102.0% during the 4th quarter. Millennium Management LLC now owns 446,301 shares of the company’s stock worth $3,843,000 after buying an additional 225,317 shares during the last quarter. Susquehanna International Group LLP lifted its holdings in Lucira Health by 56.0% during the 4th quarter. Susquehanna International Group LLP now owns 164,512 shares of the company’s stock worth $1,416,000 after buying an additional 59,041 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Lucira Health by 11.1% during the 4th quarter. Geode Capital Management LLC now owns 93,436 shares of the company’s stock worth $804,000 after buying an additional 9,349 shares during the last quarter. D. E. Shaw & Co. Inc. purchased a new stake in Lucira Health during the 4th quarter worth about $642,000. Finally, Wells Fargo & Company MN lifted its holdings in Lucira Health by 364.0% during the 2nd quarter. Wells Fargo & Company MN now owns 81,154 shares of the company’s stock worth $538,000 after buying an additional 63,665 shares during the last quarter. 62.61% of the stock is owned by institutional investors.

A number of brokerages have recently weighed in on LHDX. Lifesci Capital raised Lucira Health from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 22nd. Zacks Investment Research raised Lucira Health from a “hold” rating to a “buy” rating and set a $4.00 price objective for the company in a research note on Wednesday, March 9th.

About Lucira Health (Get Rating)

Lucira Health, Inc, a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits.

Featured Stories

Receive News & Ratings for Lucira Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucira Health and related companies with MarketBeat.com's FREE daily email newsletter.